{"id":54057,"date":"2026-06-09T21:43:39","date_gmt":"2026-06-09T21:43:39","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=54057"},"modified":"2026-06-10T15:46:44","modified_gmt":"2026-06-10T15:46:44","slug":"once-weekly-oral-islatravir-lenacapavir-meets-48-week-primary-endpoint-in-phase-3-studies","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/54057","title":{"rendered":"Once-weekly oral islatravir\/lenacapavir meets 48-week primary endpoint in phase 3 studies"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>On 8 June 2026, Gilead Sciences and Merck\/MSD released top-line results of the phase 3 ISLEND-1 and ISLEND-2 studies using an experimental once-weekly oral formulation of islatravir 2 mg\/lenacapavir 300 mg (ISL\/LEN).<\/strong><\/p>\n<p>The press statement only noted that the primary endpoints of non-inferiority at week 48 had been met for both studies, compared to either daily Biktarvy or standard of care ART, respectively.<\/p>\n<p>More detailed results will be presented at future meetings.<\/p>\n<p>No unexpected side effects were reported.<\/p>\n<p>Although the press release notes that results will be filed with global regulatory authorities, these are not specified.<\/p>\n<p>Some agencies might require longer follow-up out to 96 weeks.<\/p>\n<p>Reference<\/p>\n<p>Gilead and Merck\/MSD Press Release. Islatravir\/Lenacapavir has the Potential to be the First Approved Long-Acting Oral HIV Treatment Taken Once-Weekly. (8 June 2026).<br \/>\n<a href=\"https:\/\/www.gilead.com\/news\/news-details\/2026\/gilead-and-merck-announce-positive-topline-results-from-two-phase-3-studies-evaluating-islatravirlenacapavir-an-oral-once-weekly-hiv-treatment\">https:\/\/www.gilead.com\/news\/news-details\/2026\/gilead-and-merck-announce-positive-topline-results-from-two-phase-3-studies-evaluating-islatravirlenacapavir-an-oral-once-weekly-hiv-treatment<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 8 June 2026, Gilead Sciences and Merck\/MSD released top-line results of the phase 3 ISLEND-1 and ISLEND-2 studies using an experimental once-weekly oral formulation of islatravir 2 mg\/lenacapavir 300 mg (ISL\/LEN). The press statement only &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[163,3],"tags":[],"class_list":["post-54057","post","type-post","status-publish","format-standard","hentry","category-early-access","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/54057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=54057"}],"version-history":[{"count":3,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/54057\/revisions"}],"predecessor-version":[{"id":54061,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/54057\/revisions\/54061"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=54057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=54057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=54057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}